T1	Participants 82 124	patients with primary hypercholesterolemia
T2	Participants 441 503	827 patients with baseline low-density lipoprotein cholesterol
T3	Participants 623 642	were randomized 3:1
T4	Participants 941 1017	Response to ezetimibe was generally consistent across all subgroups analyzed
